Novo Nordisk stock falls as heart drug trials are halted while obesity trial delivers upbeat data

Published on 09/07/2026 at 23:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novo Nordisk stock faces pressure after the company halted two additional ziltivekimab heart-drug trials, even as new STEP Young obesity data underline the strength of its core GLP-1 franchise. Analysts now weigh pipeline risks against continued growth in obesity treatments.

Sterile Fertigungslinie für Insulin-Pens in moderner Pharma-Produktionsanlage — Novo Nordisk A/S (ISIN DK0060534915) produziert Insulin-Pens in modernster steriler Fertigungsanlage mit Robotertechnik effizient, Illustration mit AI erstellt.

Novo Nordisk A/S (ISIN DK0060534915) stock is trading below its recent highs after the company halted two more clinical trials for its experimental heart drug ziltivekimab, even as fresh phase 3 data from the STEP Young obesity trial released on September 7, 2026 highlight continued strength in its semaglutide franchise.Reuters For investors, the contrast between cardiovascular setbacks and obesity momentum is now central to the Novo Nordisk stock story as of September 7, 2026.

Heart drug trials halted, obesity data impress

According to Reuters, Novo Nordisk announced on September 7, 2026 that it had halted two additional trials of its experimental cardiovascular drug ziltivekimab after earlier disappointing late-stage study results, further denting efforts to diversify beyond obesity and diabetes. The termination adds to an earlier setback in a late-stage study and has sharpened concerns about the company’s growth path outside its GLP-1 pillar.MarketScreener

On the same day, Novo Nordisk reported first results from the STEP Young phase 3 trial, in which children aged 6 to under 12 with obesity received once-weekly semaglutide plus lifestyle intervention for 68 weeks. The company said that 40.4 percent of participants treated with semaglutide were no longer classified as having obesity at the end of the study period, underscoring robust efficacy in a challenging pediatric population.Novo Nordisk IR via Ritzau This figure marks a significant clinical impact when compared with the baseline condition that all enrolled children met the criteria for obesity at trial start, effectively moving more than two in five treated children out of that category over roughly 16 months.

Stock price, recent performance and analyst tension

Market data from MarketScreener show Novo Nordisk shares changing hands at 298.62 Danish kroner in estimated real-time trading on September 7, 2026, down 0.09% on the day and modestly above the latest official closing price of 298.90 kroner. Over the preceding five sessions, the stock gained 2.21%, while the year-to-date performance remains negative at minus 8.12%, illustrating how the recent rebound has not yet erased the broader 2026 drawdown.MarketScreener

The same overview places the average analyst price target at 309.73 kroner, implying about 3.62% upside from the latest quote of 298.62 kroner.MarketScreener In other words, the stock currently trades a few percentage points below what the consensus regards as fair value, reflecting a market divided between confidence in obesity-driven cash flows and caution about pipeline setbacks. A prior analysis highlighted that the shares sit roughly 27 percent below their 52-week high of 54.86 euros in Frankfurt terms, even after a weekly rise of 2.8 percent, showing how 2026 has been a year of mean reversion rather than relentless gains.MarketScreener summary of Frankfurt quote

Pipeline risks versus core GLP-1 strength

The move to stop two more ziltivekimab trials follows an earlier miss of a late-stage study goal, leading some analysts to argue that the drug is “effectively out of the running” as a major growth driver and reinforcing a bear case that leans heavily on patent-expiry risk later in the decade.Ad hoc analysis of Novo Nordisk According to a recent analyst summary, houses such as Deutsche Bank and Citi have adopted a more cautious stance, both assigning Sell ratings with price targets around 265 kroner and explicitly citing slower expected growth and uncertainty ahead of the upcoming capital markets day on September 21, 2026.MarketScreener analyst snapshot

By contrast, other banks maintain more neutral views. One summary notes that a global bank has kept a Neutral rating and a 275-kroner target after management meetings, pointing to the planned launch of oral Wegovy as a potential catalyst and emphasizing that GLP-1 demand trends remain structurally supportive despite near-term volatility.MarketScreener analyst snapshot This divergence creates a “two-speed reality” for Novo Nordisk stock: the GLP-1 business continues to generate strong revenue and margin profiles, while the non-obesity pipeline faces pressure, especially in cardiometabolic indications where regulators and physicians are demanding clearer benefit-risk evidence.

Latest reported financials and growth backdrop

Recent earnings commentary highlights that Novo Nordisk’s most recently reported results, covering the latest quarter of 2026, showed continued top-line growth in its obesity and diabetes portfolio, with GLP-1 revenues expanding at a double-digit rate versus the same period a year earlier. In that quarter, total sales from obesity treatments were reported to have risen by a mid-teens percent range compared with the prior year’s level, supporting management’s guidance for solid full-year revenue growth in the high-single to low-double-digit percent band.GuruFocus

At the same time, margin resilience remains a key part of the equity story. According to a valuation analysis, Novo Nordisk sustains a dividend yield of 3.86% on its US listing, backed by a payout ratio of about 50% and three-year dividend growth of 27.8%, all while maintaining a profitability profile that earns a GF Score of 76 out of 100.GuruFocus These numbers indicate that even with pipeline disappointments, the company still generates enough cash to fund shareholder returns and investments in new trials, a balance that investors will scrutinize closely when management presents its medium-term roadmap later in September 2026.

Product focus: Wegovy and semaglutide franchise

Novo Nordisk’s flagship GLP-1 product, Wegovy, together with related semaglutide formulations, remains central to the company’s growth outlook. Recent coverage notes that Chinese regulators accepted the company’s filing for an oral Wegovy tablet in late August 2026, opening the door to a major new market where obesity prevalence is rising and where oral therapies could expand access beyond injectable treatments.MarketScreener summary The newly disclosed STEP Young trial adds a pediatric dimension to semaglutide’s clinical footprint, suggesting potential label expansion over time if regulators agree with the risk-benefit balance in younger patients.

For shareholders, the message from these developments is that the semaglutide franchise continues to deepen and broaden across geographies and age groups, while the broader pipeline is being reshaped by the ziltivekimab decision. The upcoming capital markets day on September 21, 2026 is therefore likely to devote significant time to explaining how management intends to reallocate R&D resources between obesity, diabetes and cardiovascular programs, and how these choices might influence revenue growth and margin trajectories up to 2030.Ad hoc analysis of capital markets day

Stock level and investor takeaway

As of September 7, 2026, Novo Nordisk stock on Nasdaq Copenhagen is quoted at 298.62 kroner, roughly 3.62% below the average analyst target of 309.73 kroner and modestly above the latest official close.MarketScreener With the shares still down 8.12% since the start of 2026 and trading below prior highs, the market is clearly weighing the downside risk from halted heart-drug trials against the upside potential from expanding semaglutide use in adults and children.